ClinicalTrials.gg
CompletedNCT00522821SubklasseUpdated Apr 6, 2015

Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response

A Phase 4 interventional study of intravenous immunoglobulins and antibiotics in IgG Deficiency and Infections, sponsored by Prothya Biosolutions. Completed at 9 sites in Netherlands. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2015-04-06.

Sponsored by Prothya Biosolutions · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
5 Years and older
Sex
All
01

Study summary

There is no consensus on the treatment of patients with recurrent infections and isolated immunoglobulin G (IgG)-subclass deficiency and/or selective antipolysaccharide antibody deficiency. Therefore, the Dutch Inter University Working Party will start a study in which the treatment with antibiotics is compared with intravenous immunoglobulin therapy with respect to clinical outcome measures in both children and adults with this disorder.

Read the detailed description

There is no consensus on the treatment of patients with recurrent infections and isolated IgG-subclass deficiency and/or selective antipolysaccharide antibody deficiency. At present, there are no robust criteria to predict which patient will or will not respond adequately to antibiotic treatment or to IVIG. Furthermore, it is unknown whether IVIG treatment improves the quality of life in these patients. Therefore, the Dutch InterUniversity Working Party intends to start a study in this patient group. In this study, treatment for a year with antibiotics will be compared with a year intravenous immunoglobulin therapy with respect to clinical outcome measures in both children and adults with this disorder.

The patient will visit the clinic every 3 months during which laboratory tests and physiological measurements will be performed. Moreover the occurrence of infections and fever, the use of antibiotics, hospital admissions, and quality of life will be documented.

The study should result in a national harmonization in the treatment of this patient group. To this end, the results of the study will be used to compile a treatment protocol for this group of patients in the Netherlands and if applicable also in other countries worldwide.

02

Conditions studied

  • IgG Deficiency
  • Infections

Browse trials for

Keywords

  • IgG subclass deficiency
  • Anti-polysaccharide deficiency
  • therapy
  • Immunoglobulins, Intravenous
  • co-trimoxazole
03

In context

Infections

2,097 studies on the registry are indexed under Infections; 361 are open to participants now.

This study's enrollment of 55 is below the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Prothya Biosolutions is the lead sponsor of 15 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • IgG subclass deficiency and/or (selective) antipolysaccharide antibody deficiency
  • At least 2 physician documented infections before the start of the current treatment or in the last 6 months for newly diagnosed patients.
  • Total serum IgG > 4 g/l
  • ≥ 5 years of age

Exclusion criteria

Exclusion Criteria:

  • Treatment with any other drug within 7 days prior to study entry, or previous enrolment in this study
  • Allergic reactions against human plasma/plasma products, or co-trimoxazole
  • An ongoing progressive terminal disease
  • Pregnancy or lactation
  • History of (transient) cerebrovascular accident or coronary insufficiency
  • Renal insufficiency (plasma creatinin > 115 µmol/L; or creatinin clearance \<20 ml/min)
  • An ongoing active disease causing general symptoms e.g. chronic active hepatitis or persistent enterovirus infection with ongoing systemic complaints
  • Detectable anti-IgA antibodies
  • Active systemic lupus erythematosus (SLE)
  • Glucose-6-phosphate hydrogenase deficiency
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Other
    Antibiotics

    A: co-trimoxazole prophylactically for 12 months followed by intravenous immunoglobulin treatment for 12 months. Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given.

    Drug: intravenous immunoglobulins · Drug: antibiotics

  • Other
    intravenous immunoglobulins

    B: intravenous immunoglobulin treatment for 12 months followed by co-trimoxazole prophylactically for 12 months. Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given.

    Drug: intravenous immunoglobulins · Drug: antibiotics

Interventions

  • * Adults: 600 mg/kg bodyweight every 3 weeks * Children: 800 mg/kg bodyweight every 3 week

    Also known as: Nanogam

  • Drugantibiotics

    * Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid. * Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid.

    Also known as: co-trimoxazol, if not lorated: azitromycine

06

What researchers measure

Primary outcomes

  1. the number, duration and type of infection (including use of antibiotics to treat infections), days of fever, hospital admissions and, if applicable, days absent from school or work due to infections.

    Time frame: 27 months

Secondary outcomes

  1. Safety will be monitored by occurrence of adverse events, vital signs, and laboratory measurements.

    Time frame: 27 months

07

Study locations

9 sites
  • AMC
    Amsterdam, Netherlands
  • VU
    Amsterdam, Netherlands
  • Jeroen Bosch Ziekenhuis
    Den Bosch, Netherlands
  • UMCG
    Groningen, Netherlands
  • LUMC
    Leiden, Netherlands
  • AZM
    Maastricht, Netherlands
  • UMC St Radboud
    Nijmegen, Netherlands
  • Erasmus MC
    Rotterdam, Netherlands
  • UMCU
    Utrecht, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2007
First posted
Aug 30, 2007
Start
Nov 2007
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Last update
Apr 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00522821
Lead sponsor
Prothya Biosolutions
Responsible party
Sponsor
First posted
Aug 30, 2007
Start date
Nov 2007
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Apr 6, 2015

Study contacts

J T van Dissel, PhD, MD
principal investigator · LUMC
T W Kuijpers, PhD, MD
principal investigator · AIDS Malignancy Consortium
E AM Sanders, PhD, MD
principal investigator · UMCU

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion